Last Price$89.69NASDAQ Previous Close - Last Trade as of 4:00PM ET 10/23/20
NASDAQ 15-minute delayed Bid/Ask Quotes
Today's Change0(0.00%)
Bid (Size)$87.80 (1)
Ask (Size)$89.69 (77)
Day Low / HighN/A - N/A
Volume652.0 K

Eli Lilly and Incyte Get Positive Opinion From European Medicines Agency's CHMP for Baricitinib to Treat Atopic Dermatitis

10:52AM ET 9/18/2020 MT Newswires
Eli Lilly and Company (LLY) and Incyte (INCY) said Friday they received a positive opinion from the European Medicines Agency's Committee for Medicinal Products for Human Use for the use of baricitinib to treat adult patients with moderate to severe atopic dermatitis who are candidates for systemic therapy.

Baricitinib, marketed as Olumiant, is already approved in more than 70 countries as a treatment for adults with moderately to severely active rheumatoid arthritis.

A final decision from the European Commission is expected in the one or two months.

Price: 153.55, Change: +1.08, Percent Change: +0.71